Is Intellia Therapeutics a good investment?
Healthcare is undergoing a genomics revolution, and Intellia Therapeutics (NASDAQ: NTLA) is leading the way. Founded by Jennifer Doudna, who won the 2020 Nobel Prize in Chemistry for her CRISPR-Cas9 genome editing discovery.
In accordance with the recently published financial statements, Intellia Thera CS has a Current Valuation of 10.51 B. This is 26.83% lower than that of the Healthcare sector and 126.24% higher than that of the Biotechnology industry. The current valuation for all United States stocks is 36.78% higher than that of the company.
